Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

1.

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX.

Bladder Cancer. 2016 Jan 7;2(1):37-47.

2.

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.

Lebret T, Neuzillet Y, Houede N, Rebouissou S, Bernard-Pierrot I, De Reynies A, Benhamou S, Allory Y, Radvanyi F.

Mol Cell Oncol. 2015 Jul 9;2(4):e999507. doi: 10.1080/23723556.2014.999507. eCollection 2015 Oct-Dec.

3.

A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1.

Eloy P, Dehainault C, Sefta M, Aerts I, Doz F, Cassoux N, Lumbroso le Rouic L, Stoppa-Lyonnet D, Radvanyi F, Millot GA, Gauthier-Villars M, Houdayer C.

PLoS Genet. 2016 Feb 29;12(2):e1005888. doi: 10.1371/journal.pgen.1005888. eCollection 2016 Feb.

4.

L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.

Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T.

Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461580
5.

A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.

Remy E, Rebouissou S, Chaouiya C, Zinovyev A, Radvanyi F, Calzone L.

Cancer Res. 2015 Oct 1;75(19):4042-52. doi: 10.1158/0008-5472.CAN-15-0602. Epub 2015 Aug 3. Erratum in: Cancer Res. 2016 Jan 15;76(2):505.

PMID:
26238783
6.

CoRegNet: reconstruction and integrated analysis of co-regulatory networks.

Nicolle R, Radvanyi F, Elati M.

Bioinformatics. 2015 Sep 15;31(18):3066-8. doi: 10.1093/bioinformatics/btv305. Epub 2015 May 14.

7.

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P.

Eur J Cancer. 2015 Jan;51(1):45-54. doi: 10.1016/j.ejca.2014.10.009. Epub 2014 Nov 15.

PMID:
25459391
8.

Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.

Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C, López-Bigas N, Kamoun A, Neuzillet Y, Gestraud P, Grieco L, Rebouissou S, de Reyniès A, Benhamou S, Lebret T, Southgate J, Barillot E, Allory Y, Zinovyev A, Radvanyi F.

Cell Rep. 2014 Nov 20;9(4):1235-45. doi: 10.1016/j.celrep.2014.10.035. Epub 2014 Nov 13.

9.

Pepper: cytoscape app for protein complex expansion using protein-protein interaction networks.

Winterhalter C, Nicolle R, Louis A, To C, Radvanyi F, Elati M.

Bioinformatics. 2014 Dec 1;30(23):3419-20. doi: 10.1093/bioinformatics/btu517. Epub 2014 Aug 18.

10.

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.

Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F.

Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970.

11.

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.

Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J, Gudjonsson SA, Sigurdsson A, Stacey SN, Gudmundsson J, Johannsdottir H, Alexiusdottir K, Petursdottir V, Nikulasson S, Geirsson G, Jonsson T, Aben KK, Grotenhuis AJ, Verhaegh GW, Dudek AM, Witjes JA, van der Heijden AG, Vrieling A, Galesloot TE, De Juan A, Panadero A, Rivera F, Hurst C, Bishop DT, Sak SC, Choudhury A, Teo MT, Arici C, Carta A, Toninelli E, de Verdier P, Rudnai P, Gurzau E, Koppova K, van der Keur KA, Lurkin I, Goossens M, Kellen E, Guarrera S, Russo A, Critelli R, Sacerdote C, Vineis P, Krucker C, Zeegers MP, Gerullis H, Ovsiannikov D, Volkert F, Hengstler JG, Selinski S, Magnusson OT, Masson G, Kong A, Gudbjartsson D, Lindblom A, Zwarthoff E, Porru S, Golka K, Buntinx F, Matullo G, Kumar R, Mayordomo JI, Steineck DG, Kiltie AE, Jonsson E, Radvanyi F, Knowles MA, Thorsteinsdottir U, Kiemeney LA, Stefansson K.

Hum Mol Genet. 2014 Oct 15;23(20):5545-57. doi: 10.1093/hmg/ddu264. Epub 2014 May 26.

12.

Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses.

Srinivasan H, Allory Y, Sill M, Vordos D, Alhamdani MS, Radvanyi F, Hoheisel JD, Schröder C.

Proteomics. 2014 Jun;14(11):1333-42. doi: 10.1002/pmic.201300320. Epub 2014 Apr 29.

PMID:
24610664
13.

PRC2-independent chromatin compaction and transcriptional repression in cancer.

Vallot C, Hérault A, Boyle S, Bickmore WA, Radvanyi F.

Oncogene. 2015 Feb 5;34(6):741-51. doi: 10.1038/onc.2013.604. Epub 2014 Jan 27.

PMID:
24469045
14.

Integrative modelling of the influence of MAPK network on cancer cell fate decision.

Grieco L, Calzone L, Bernard-Pierrot I, Radvanyi F, Kahn-Perlès B, Thieffry D.

PLoS Comput Biol. 2013 Oct;9(10):e1003286. doi: 10.1371/journal.pcbi.1003286. Epub 2013 Oct 24. Erratum in: PLoS Comput Biol. 2013 Nov;9(11). doi:10.1371/annotation/90e5e4be-952b-42b8-b56d-46baae3479ed.

15.

New aminopyrimidine derivatives as inhibitors of the TAM family.

Traoré T, Cavagnino A, Saettel N, Radvanyi F, Piguel S, Bernard-Pierrot I, Stoven V, Legraverend M.

Eur J Med Chem. 2013;70:789-801. doi: 10.1016/j.ejmech.2013.10.037. Epub 2013 Oct 22.

PMID:
24239626
16.

A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation.

Mahmood SF, Gruel N, Chapeaublanc E, Lescure A, Jones T, Reyal F, Vincent-Salomon A, Raynal V, Pierron G, Perez F, Camonis J, Del Nery E, Delattre O, Radvanyi F, Bernard-Pierrot I.

Carcinogenesis. 2014 Mar;35(3):670-82. doi: 10.1093/carcin/bgt351. Epub 2013 Oct 22.

17.

An essential role for decorin in bladder cancer invasiveness.

El Behi M, Krumeich S, Lodillinsky C, Kamoun A, Tibaldi L, Sugano G, De Reynies A, Chapeaublanc E, Laplanche A, Lebret T, Allory Y, Radvanyi F, Lantz O, Eiján AM, Bernard-Pierrot I, Théry C.

EMBO Mol Med. 2013 Dec;5(12):1835-51. doi: 10.1002/emmm.201302655. Epub 2013 Oct 20.

18.

PI3K/AKT pathway activation in bladder carcinogenesis.

Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.

Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24.

19.

Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma.

Bourdeaut F, Miquel C, Richer W, Grill J, Zerah M, Grison C, Pierron G, Amiel J, Krucker C, Radvanyi F, Brugieres L, Delattre O.

Pediatr Blood Cancer. 2014 Feb;61(2):383-6. doi: 10.1002/pbc.24765. Epub 2013 Sep 20.

PMID:
24115570
20.

PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.

Mahmood SF, Gruel N, Nicolle R, Chapeaublanc E, Delattre O, Radvanyi F, Bernard-Pierrot I.

Am J Pathol. 2013 Nov;183(5):1634-44. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.

PMID:
24051013
Items per page

Supplemental Content

Loading ...
Write to the Help Desk